Periodontal Disease - Pipeline Review, H2 2012

Transcription

1 Brochure More information from Periodontal Disease - Pipeline Review, H Description: Periodontal Disease Pipeline Review, H Summary Global Markets Direct s, 'Periodontal Disease - Pipeline Review, H2 2012', provides an overview of the Periodontal Disease therapeutic pipeline. This report provides information on the therapeutic development for Periodontal Disease, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Periodontal Disease. 'Periodontal Disease - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Periodontal Disease. - A review of the Periodontal Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Periodontal Disease pipeline on the basis of route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Periodontal Disease. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players with the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Periodontal Disease pipeline depth and focus of Periodontal Disease therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. Keywords Periodontal Disease Therapeutic Products under Development, Key Players in Periodontal Disease Therapeutics, Periodontal Disease Pipeline Overview, Periodontal Disease Pipeline, Periodontal Disease Pipeline Assessment Contents: 2 List of Tables 5 List of Figures 5 Introduction 6

2 REPORT COVERAGE 6 Periodontal Disease Overview 7 Therapeutics Development 8 An Overview of Pipeline Products for Periodontal Disease 8 Periodontal Disease Therapeutics under Development by Companies 10 Periodontal Disease Therapeutics under Investigation by Universities/Institutes 11 Late Stage Products 13 Comparative Analysis 13 Mid Clinical Stage Products 14 Comparative Analysis 14 Early Clinical Stage Products 15 Comparative Analysis 15 Discovery and Pre-Clinical Stage Products 16 Comparative Analysis 16 Periodontal Disease Therapeutics Products under Development by Companies 17 Periodontal Disease Therapeutics Products under Investigation by Universities/Institutes 18 Companies Involved in Periodontal Disease Therapeutics Development 19 Enzo Biochem, Inc. 19 IMAGENETIX, INC 20 Kaken Pharmaceutical Co.,Ltd. 21 CSL Limited 22 Yuhan Corporation 23 Biomedical Development Corporation. 24 Periodontal Disease Therapeutics Assessment 25 Assessment by Monotherapy Products 25 Assessment by Combination Products 26 Assessment by Route of Administration 27 Assessment by Molecule Type 29 Drug Profiles 31 POD CRC-OHS - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 1-Tetradecanol Complex - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 KCB-1D - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 Enzo-D58 - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Tetracycline + Metronidazole + Amoxicillin - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 Metronidazole + Amoxicillin - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 Tetracycline - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Curcuminoids - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 Iocide - Drug Profile 41 Product Description 41

3 Mechanism of Action 41 R&D Progress 41 Iocide - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 Omega 3 PUFA + Aspirin - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 Metronidazole - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 Camella Sinensis - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 PerioPatch - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 Cell Sheet Pellets + Cell Sheet Fragment - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Aroeira - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 Green Propolis - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 YH Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 Periodontal Disease Therapeutics Drug Profile Updates 51 Periodontal Disease Therapeutics - Dormant Products 52 Periodontal Disease Product Development Milestones 54 Featured News & Press Releases 54 Mar 30, 2012: Kaken Pharma To Initiate Additional Phase III Trial For KCB-1D 54 Aug 12, 2009: Imagenetix Announces Publication Of Results From 1-TDC Boston University Periodontal Study In The Journal Of Periodontology 54 Jun 01, 2007: Periodontal Study On Imagenetix Compound 1-TDC Published In Journal Of Periodontology 54 Dec 11, 2006: Imagenetix Receives FDA Clearance To Begin Pre-IND Safety Studies On Anti-Inflammatory Compound 55 Jun 01, 2006: Imagenetix Announces Positive Safety Studies On Anti-Inflammatory Compound, 1-TDC 56 May 22, 2006: CombinatoRx Reports Second Positive Phase 2 Study with CRx May 08, 2006: Imagenetix Announces 1-Tetradecanol Complex Acts To Inhibit Bacteria And Enzymes Associated With Oral Disease, Sepsis And Inflammation 56 Oct 21, 2004: Kaken Pharmaceutical Announces Results Of Early Phase II Clinical Trial On KCB-1D 57 Appendix 58 Methodology 58 Coverage 58 Secondary Research 58 Primary Research 58 Expert Panel Validation 58 Contact Us 59 Disclaimer 59 List of Tables

4 Number of Products Under Development for Periodontal Disease, H Products under Development for Periodontal Disease Comparative Analysis, H Number of Products under Development by Companies, H Number of Products under Investigation by Universities/Institutes, H Comparative Analysis by Late Stage Development, H Comparative Analysis by Mid Clinical Stage Development, H Comparative Analysis by Early Clinical Stage Development, H Comparative Analysis by Discovery and Pre-Clinical Stage Development, H Products under Development by Companies, H Products under Investigation by Universities/Institutes, H Enzo Biochem, Inc., H IMAGENETIX, INC, H Kaken Pharmaceutical Co.,Ltd., H CSL Limited, H Yuhan Corporation, H Biomedical Development Corporation., H Assessment by Monotherapy Products, H Assessment by Combination Products, H Assessment by Stage and Route of Administration, H Assessment by Stage and Molecule Type, H Periodontal Disease Therapeutics Drug Profile Updates 51 Periodontal Disease Therapeutics Dormant Products 52 Periodontal Disease Therapeutics Dormant Products (Contd..1) 53 List of Figures Number of Products under Development for Periodontal Disease, H Products under Development for Periodontal Disease Comparative Analysis, H Products under Development by Companies, H Products under Investigation by Universities/Institutes, H Late Stage Products, H Mid Clinical Stage Products, H Early Clinical Stage Products, H Discovery and Pre-Clinical Stage Products, H Assessment by Monotherapy Products, H Assessment by Combination Products, H Assessment by Route of Administration, H Assessment by Stage and Route of Administration, H Assessment by Molecule Type, H Assessment by Stage and Molecule Type, H Ordering: Order Online - Order by Fax - using the form below Order by Post - print the order form below and send to Research and Markets, Guinness Centre, Taylors Lane, Dublin 8, Ireland.

5 Page 1 of 2 Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to (from USA) or (from Rest of World). If you have any questions please visit Order Information Please verify that the product information is correct and select the format(s) you require. Product Name: Periodontal Disease - Pipeline Review, H Web Address: Office Code: Product Formats Please select the product formats and quantity you require: SC Electronic (PDF) - Single User: Electronic (PDF) - Site License: Electronic (PDF) - Enterprisewide: Quantity USD 2000 USD 4000 USD 6000 * The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change. Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: Last Name: Address: * Job Title: Organisation: Address: City: Postal / Zip Code: Country: Phone Number: Fax Number: * Please refrain from using free accounts when ordering (e.g. Yahoo, Hotmail, AOL)

6 Page 2 of 2 Payment Information Please indicate the payment method you would like to use by selecting the appropriate box. Pay by credit card: You will receive an with a link to a secure webpage to enter your credit card details. Pay by check: Please post the check, accompanied by this form, to: Research and Markets, Guinness Center, Taylors Lane, Dublin 8, Ireland. Pay by wire transfer: Please transfer funds to: Account number Sort code Swift code IBAN number Bank Address ULSBIE2D IE78ULSB Ulster Bank, Main Street, Blackrock, Co. Dublin, Ireland. If you have a Marketing Code please enter it below: Marketing Code: Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at Please fax this form to: (646) or (646) From USA or From Rest of World